Systematic in silico Evaluation of Leishmania spp. Proteomes for Drug Discovery

Leishmaniasis is a group of neglected infectious diseases, with approximately 1. 3 million new cases each year, for which the available therapies have serious limitations. Therefore, it is extremely important to apply efficient and low-cost methods capable of selecting the best therapeutic targets t...

Full description

Bibliographic Details
Main Authors: Crhisllane Rafaele dos Santos Vasconcelos, Antonio Mauro Rezende
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Chemistry
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fchem.2021.607139/full
_version_ 1823943534707736576
author Crhisllane Rafaele dos Santos Vasconcelos
Crhisllane Rafaele dos Santos Vasconcelos
Antonio Mauro Rezende
Antonio Mauro Rezende
author_facet Crhisllane Rafaele dos Santos Vasconcelos
Crhisllane Rafaele dos Santos Vasconcelos
Antonio Mauro Rezende
Antonio Mauro Rezende
author_sort Crhisllane Rafaele dos Santos Vasconcelos
collection DOAJ
description Leishmaniasis is a group of neglected infectious diseases, with approximately 1. 3 million new cases each year, for which the available therapies have serious limitations. Therefore, it is extremely important to apply efficient and low-cost methods capable of selecting the best therapeutic targets to speed up the development of new therapies against those diseases. Thus, we propose the use of integrated computational methods capable of evaluating the druggability of the predicted proteomes of Leishmania braziliensis and Leishmania infantum, species responsible for the different clinical manifestations of leishmaniasis in Brazil. The protein members of those proteomes were assessed based on their structural, chemical, and functional contexts applying methods that integrate data on molecular function, biological processes, subcellular localization, drug binding sites, druggability, and gene expression. These data were compared to those extracted from already known drug targets (BindingDB targets), which made it possible to evaluate Leishmania proteomes for their biological relevance and treatability. Through this methodology, we identified more than 100 proteins of each Leishmania species with druggability characteristics, and potential interaction with available drugs. Among those, 31 and 37 proteins of L. braziliensis and L. infantum, respectively, have never been tested as drug targets, and they have shown evidence of gene expression in the evolutionary stage of pharmacological interest. Also, some of those Leishmania targets showed an alignment similarity of <50% when compared to the human proteome, making these proteins pharmacologically attractive, as they present a reduced risk of side effects. The methodology used in this study also allowed the evaluation of opportunities for the repurposing of compounds as anti-leishmaniasis drugs, inferring potential interaction between Leishmania proteins and ~1,000 compounds, of which only 15 have already been tested as a treatment for leishmaniasis. Besides, a list of potential Leishmania targets to be tested using drugs described at BindingDB, such as the potential interaction of the DEAD box RNA helicase, TRYR, and PEPCK proteins with the Staurosporine compound, was made available to the public.
first_indexed 2024-12-17T08:00:17Z
format Article
id doaj.art-72293eb490ad4155873421565cef9ae0
institution Directory Open Access Journal
issn 2296-2646
language English
last_indexed 2024-12-17T08:00:17Z
publishDate 2021-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Chemistry
spelling doaj.art-72293eb490ad4155873421565cef9ae02022-12-21T21:57:34ZengFrontiers Media S.A.Frontiers in Chemistry2296-26462021-04-01910.3389/fchem.2021.607139607139Systematic in silico Evaluation of Leishmania spp. Proteomes for Drug DiscoveryCrhisllane Rafaele dos Santos Vasconcelos0Crhisllane Rafaele dos Santos Vasconcelos1Antonio Mauro Rezende2Antonio Mauro Rezende3Bioinformatics Plataform, Microbiology Department, Instituto Aggeu Magalhães, Recife, BrazilPosgraduate Program in Genetics, Genetics Department, Universidade Federal de Pernambuco, Recife, BrazilBioinformatics Plataform, Microbiology Department, Instituto Aggeu Magalhães, Recife, BrazilPosgraduate Program in Genetics, Genetics Department, Universidade Federal de Pernambuco, Recife, BrazilLeishmaniasis is a group of neglected infectious diseases, with approximately 1. 3 million new cases each year, for which the available therapies have serious limitations. Therefore, it is extremely important to apply efficient and low-cost methods capable of selecting the best therapeutic targets to speed up the development of new therapies against those diseases. Thus, we propose the use of integrated computational methods capable of evaluating the druggability of the predicted proteomes of Leishmania braziliensis and Leishmania infantum, species responsible for the different clinical manifestations of leishmaniasis in Brazil. The protein members of those proteomes were assessed based on their structural, chemical, and functional contexts applying methods that integrate data on molecular function, biological processes, subcellular localization, drug binding sites, druggability, and gene expression. These data were compared to those extracted from already known drug targets (BindingDB targets), which made it possible to evaluate Leishmania proteomes for their biological relevance and treatability. Through this methodology, we identified more than 100 proteins of each Leishmania species with druggability characteristics, and potential interaction with available drugs. Among those, 31 and 37 proteins of L. braziliensis and L. infantum, respectively, have never been tested as drug targets, and they have shown evidence of gene expression in the evolutionary stage of pharmacological interest. Also, some of those Leishmania targets showed an alignment similarity of <50% when compared to the human proteome, making these proteins pharmacologically attractive, as they present a reduced risk of side effects. The methodology used in this study also allowed the evaluation of opportunities for the repurposing of compounds as anti-leishmaniasis drugs, inferring potential interaction between Leishmania proteins and ~1,000 compounds, of which only 15 have already been tested as a treatment for leishmaniasis. Besides, a list of potential Leishmania targets to be tested using drugs described at BindingDB, such as the potential interaction of the DEAD box RNA helicase, TRYR, and PEPCK proteins with the Staurosporine compound, was made available to the public.https://www.frontiersin.org/articles/10.3389/fchem.2021.607139/fulldrug repurposingprotein interaction networkdrug targetsleishmaniasisLeishmania
spellingShingle Crhisllane Rafaele dos Santos Vasconcelos
Crhisllane Rafaele dos Santos Vasconcelos
Antonio Mauro Rezende
Antonio Mauro Rezende
Systematic in silico Evaluation of Leishmania spp. Proteomes for Drug Discovery
Frontiers in Chemistry
drug repurposing
protein interaction network
drug targets
leishmaniasis
Leishmania
title Systematic in silico Evaluation of Leishmania spp. Proteomes for Drug Discovery
title_full Systematic in silico Evaluation of Leishmania spp. Proteomes for Drug Discovery
title_fullStr Systematic in silico Evaluation of Leishmania spp. Proteomes for Drug Discovery
title_full_unstemmed Systematic in silico Evaluation of Leishmania spp. Proteomes for Drug Discovery
title_short Systematic in silico Evaluation of Leishmania spp. Proteomes for Drug Discovery
title_sort systematic in silico evaluation of leishmania spp proteomes for drug discovery
topic drug repurposing
protein interaction network
drug targets
leishmaniasis
Leishmania
url https://www.frontiersin.org/articles/10.3389/fchem.2021.607139/full
work_keys_str_mv AT crhisllanerafaeledossantosvasconcelos systematicinsilicoevaluationofleishmaniasppproteomesfordrugdiscovery
AT crhisllanerafaeledossantosvasconcelos systematicinsilicoevaluationofleishmaniasppproteomesfordrugdiscovery
AT antoniomaurorezende systematicinsilicoevaluationofleishmaniasppproteomesfordrugdiscovery
AT antoniomaurorezende systematicinsilicoevaluationofleishmaniasppproteomesfordrugdiscovery